|
US6218160B1
(en)
*
|
1997-10-31 |
2001-04-17 |
Roche Diagnostics Corporation |
Site-specific conjugation of glycoproteins
|
|
KR20010024326A
(ko)
*
|
1998-07-29 |
2001-03-26 |
고토 기치 |
신규한 디아미노 화합물, 폴리암산, 폴리이미드, 당해폴리이미드 막으로부터 제조된 액정 배향막 및 당해배향막을 함유하는 액정 표시소자
|
|
US6706892B1
(en)
|
1999-09-07 |
2004-03-16 |
Conjuchem, Inc. |
Pulmonary delivery for bioconjugation
|
|
EP1889639A3
(en)
*
|
1999-09-07 |
2008-04-09 |
ConjuChem Biotechnologies Inc. |
Methods and compositions containing succinimide or maleimide derivatives of antineoplastic agents, for producing long lasting antineoplastic agents
|
|
CA2383798A1
(en)
*
|
1999-09-07 |
2001-03-15 |
Conjuchem Inc. |
Pulmonary delivery for bioconjugation
|
|
PT1392359E
(pt)
|
2001-05-11 |
2010-01-27 |
Ludwig Inst For Cancer Res Ltd |
Proteínas de ligação específica e suas utilizações
|
|
US20100056762A1
(en)
|
2001-05-11 |
2010-03-04 |
Old Lloyd J |
Specific binding proteins and uses thereof
|
|
NZ511705A
(en)
*
|
2001-05-14 |
2004-03-26 |
Horticulture & Food Res Inst |
Methods and rapid immunoassay device for detecting progesterone and other steroids
|
|
US6989452B2
(en)
|
2001-05-31 |
2006-01-24 |
Medarex, Inc. |
Disulfide prodrugs and linkers and stabilizers useful therefor
|
|
RU2196604C1
(ru)
*
|
2001-12-21 |
2003-01-20 |
Северин Евгений Сергеевич |
Полипептид, являющийся аналогом рецепторсвязывающего фрагмента эпидермального фактора роста с 21-й по 31-ю аминокислоту, его конъюгат с доксорубицином и фармацевтическая композиция на его основе
|
|
US8361464B2
(en)
|
2002-03-01 |
2013-01-29 |
Immunomedics, Inc. |
Anthracycline-Antibody Conjugates for Cancer Therapy
|
|
EP1525002A1
(en)
*
|
2002-07-24 |
2005-04-27 |
Universite Catholique De Louvain |
Method for the synthesis of anthracycline-peptide conjugates
|
|
US20040047917A1
(en)
*
|
2002-09-06 |
2004-03-11 |
Stephen Wilson |
Drug delivery and targeting with vitamin B12 conjugates
|
|
AU2011236095B2
(en)
*
|
2003-01-24 |
2013-08-01 |
Immunomedics, Inc. |
Anthracycline-antibody conjugates
|
|
US20040202666A1
(en)
*
|
2003-01-24 |
2004-10-14 |
Immunomedics, Inc. |
Anti-cancer anthracycline drug-antibody conjugates
|
|
WO2004073656A2
(en)
|
2003-02-20 |
2004-09-02 |
Seattle Genetics, Inc. |
Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
|
|
US7053191B2
(en)
*
|
2003-05-21 |
2006-05-30 |
Solux Corporation |
Method of preparing 4-R-substituted 4-demethoxydaunorubicin
|
|
EP1668424A4
(en)
*
|
2003-09-12 |
2009-11-25 |
Onkor Pharmaceuticals Inc |
MAGNETICALLY DETERMINABLE PARTICLES WITH MAGNETIC COMPONENTS AND BIOCOMPATIBLE POLYMERS FOR THE LOCAL DELIVERY OF BIOLOGICALLY ACTIVE ACTIVE SUBSTANCES
|
|
MXPA06013413A
(es)
*
|
2004-05-19 |
2007-01-23 |
Medarex Inc |
Enlazadores quimicos y conjugados de los mismos.
|
|
RU2402548C2
(ru)
*
|
2004-05-19 |
2010-10-27 |
Медарекс, Инк. |
Химические линкеры и их конъюгаты
|
|
US7541330B2
(en)
*
|
2004-06-15 |
2009-06-02 |
Kosan Biosciences Incorporated |
Conjugates with reduced adverse systemic effects
|
|
WO2006015318A2
(en)
*
|
2004-07-30 |
2006-02-09 |
Biogen Idec Inc. |
Antibody conjugated to a drug moiety via a poptidic linker
|
|
ATE476994T1
(de)
|
2004-11-30 |
2010-08-15 |
Curagen Corp |
Antikörper gegen gpnmb und ihre verwendungen
|
|
JP2008529556A
(ja)
*
|
2005-02-18 |
2008-08-07 |
メダレックス， インク． |
前立腺特異的膜抗原（ｐｓｍａ）に対するヒトモノクローナル抗体
|
|
CA2602849C
(en)
*
|
2005-03-30 |
2013-06-04 |
Saladax Biomedical Inc. |
Doxorubicin immunoassay
|
|
US7714016B2
(en)
*
|
2005-04-08 |
2010-05-11 |
Medarex, Inc. |
Cytotoxic compounds and conjugates with cleavable substrates
|
|
JP5290756B2
(ja)
*
|
2005-09-26 |
2013-09-18 |
メダレックス インコーポレイテッド |
抗体−薬剤コンジュゲート及びその使用
|
|
EP1940789B1
(en)
|
2005-10-26 |
2011-11-23 |
Medarex, Inc. |
Methods and compounds for preparing cc-1065 analogs
|
|
WO2007059404A2
(en)
|
2005-11-10 |
2007-05-24 |
Medarex, Inc. |
Duocarmycin derivatives as novel cytotoxic compounds and conjugates
|
|
AU2007248473B2
(en)
|
2006-05-05 |
2011-01-27 |
The Regents Of The University Of Michigan |
Bivalent Smac mimetics and the uses thereof
|
|
ES2523915T5
(es)
|
2006-12-01 |
2022-05-26 |
Seagen Inc |
Agentes de unión a la diana variantes y usos de los mismos
|
|
TWI412367B
(zh)
|
2006-12-28 |
2013-10-21 |
Medarex Llc |
化學鏈接劑與可裂解基質以及其之綴合物
|
|
WO2008091701A2
(en)
|
2007-01-25 |
2008-07-31 |
Dana-Farber Cancer Institute |
Use of anti-egfr antibodies in treatment of egfr mutant mediated disease
|
|
JP2010519310A
(ja)
|
2007-02-21 |
2010-06-03 |
メダレックス インコーポレイテッド |
単一のアミノ酸を有する化学リンカーおよびその複合体
|
|
CA2680854C
(en)
|
2007-03-15 |
2017-02-14 |
Ludwig Institute For Cancer Research |
Treatment method using egfr antibodies and src inhibitors and related formulations
|
|
EP2132312B1
(en)
|
2007-03-27 |
2016-01-27 |
Sea Lane Biotechnologies,llc. |
Constructs and libraries comprising antibody surrogate light chain sequences
|
|
MX2010001757A
(es)
|
2007-08-14 |
2010-09-14 |
Ludwig Inst Cancer Res |
Anticuerpo monoclonal 175 que activa el receptor egf y derivados y usos del mismo.
|
|
EP3241846B1
(en)
|
2007-10-04 |
2022-02-23 |
ZymoGenetics, Inc. |
B7 family member zb7h6 and related compositions and methods
|
|
US8357785B2
(en)
*
|
2008-01-08 |
2013-01-22 |
Solux Corporation |
Method of aralkylation of 4′-hydroxyl group of anthracylins
|
|
MX2010007767A
(es)
|
2008-01-18 |
2010-08-09 |
Medimmune Llc |
Anticuerpos manipulados con cisteina para conjugacion especifica de sitio.
|
|
CA2761681A1
(en)
|
2009-05-13 |
2010-11-18 |
Sea Lane Biotechnologies, Llc |
Neutralizing molecules to influenza viruses
|
|
US20120213705A1
(en)
|
2009-06-22 |
2012-08-23 |
Medimmune, Llc |
ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION
|
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
US20110076232A1
(en)
*
|
2009-09-29 |
2011-03-31 |
Ludwig Institute For Cancer Research |
Specific binding proteins and uses thereof
|
|
WO2011050242A1
(en)
|
2009-10-23 |
2011-04-28 |
Millennium Pharmaceuticals, Inc. |
Anti-gcc antibody molecules and related compositions and methods
|
|
EA024629B1
(ru)
|
2009-12-09 |
2016-10-31 |
Институт Насьональ Де Ла Сант Де Ла Решерше Медикаль |
Моноклональные антитела, связывающие b7h6, и их применение
|
|
UA115517C2
(uk)
|
2010-02-08 |
2017-11-27 |
Ейдженсіс, Інк. |
Кон'югат антитіло-лікарський засіб (adc), який зв'язується з білком 161p2f10b
|
|
CA2806252C
(en)
|
2010-07-29 |
2019-05-14 |
Xencor, Inc. |
Antibodies with modified isoelectric points
|
|
US8637642B2
(en)
|
2010-09-29 |
2014-01-28 |
Seattle Genetics, Inc. |
Antibody drug conjugates (ADC) that bind to 191P4D12 proteins
|
|
WO2012045085A1
(en)
|
2010-10-01 |
2012-04-05 |
Oxford Biotherapeutics Ltd. |
Anti-rori antibodies
|
|
EP3461847B1
(en)
|
2010-12-06 |
2020-09-23 |
Seattle Genetics, Inc. |
Humanized antibodies to liv-1 and use of same to treat cancer
|
|
JOP20210044A1
(ar)
|
2010-12-30 |
2017-06-16 |
Takeda Pharmaceuticals Co |
الأجسام المضادة لـ cd38
|
|
US8846882B2
(en)
|
2011-04-29 |
2014-09-30 |
Synbias Pharma Ag |
Method of producing 4-demethoxydaunorubicin
|
|
PH12013502421A1
(en)
|
2011-05-27 |
2014-01-06 |
Glaxo Group Ltd |
Bcma (cd269/tnfrsf17) -binding proteins
|
|
EP2736928B1
(en)
|
2011-07-28 |
2019-01-09 |
i2 Pharmaceuticals, Inc. |
Sur-binding proteins against erbb3
|
|
WO2013022855A1
(en)
|
2011-08-05 |
2013-02-14 |
Xencor, Inc. |
Antibodies with modified isoelectric points and immunofiltering
|
|
US20130058947A1
(en)
|
2011-09-02 |
2013-03-07 |
Stem Centrx, Inc |
Novel Modulators and Methods of Use
|
|
CA2851534C
(en)
|
2011-10-10 |
2023-02-14 |
Xencor, Inc. |
A method for purifying antibodies
|
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
US12466897B2
(en)
|
2011-10-10 |
2025-11-11 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
KR102052774B1
(ko)
|
2011-11-04 |
2019-12-04 |
자임워크스 인코포레이티드 |
Ｆｃ 도메인 내의 돌연변이를 갖는 안정한 이종이합체 항체 설계
|
|
WO2013096828A1
(en)
|
2011-12-22 |
2013-06-27 |
Sea Lane Biotechnologies, Llc |
Surrogate binding proteins
|
|
WO2013093809A1
(en)
|
2011-12-23 |
2013-06-27 |
Pfizer Inc. |
Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
|
|
WO2013109994A1
(en)
|
2012-01-20 |
2013-07-25 |
Sea Lane Biotechnologies, Llc |
Surrobody cojugates
|
|
ES2812849T3
(es)
|
2012-02-24 |
2021-03-18 |
Abbvie Stemcentrx Llc |
Anticuerpos anti-DLL3 y procedimientos de utilización de los mismos
|
|
KR102144069B1
(ko)
|
2012-05-15 |
2020-08-13 |
시애틀 지네틱스, 인크. |
자가-안정화 링커 접합체
|
|
CN103566377A
(zh)
|
2012-07-18 |
2014-02-12 |
上海博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
|
PT2887959T
(pt)
|
2012-08-23 |
2019-02-01 |
Seattle Genetics Inc |
Conjugados anticorpo-fármaco (adc) que se ligam a proteínas 158p1d7
|
|
EP2922818B1
(en)
|
2012-11-24 |
2018-09-05 |
Hangzhou Dac Biotech Co., Ltd |
Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
|
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
|
HRP20191865T1
(hr)
|
2013-01-14 |
2020-01-10 |
Xencor, Inc. |
Novi heterodimerni proteini
|
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
|
WO2014113510A1
(en)
|
2013-01-15 |
2014-07-24 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
|
AU2014214843A1
(en)
|
2013-02-07 |
2015-05-21 |
Immunomedics, Inc. |
Pro-drug form (P2PDox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
|
|
WO2014130879A2
(en)
|
2013-02-22 |
2014-08-28 |
Stem Centrx, Inc. |
Novel antibody conjugates and uses thereof
|
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
|
CA3093606A1
(en)
|
2013-03-15 |
2014-09-18 |
Xencor, Inc. |
Heterodimeric proteins for induction of t cells
|
|
EP3587448B1
(en)
|
2013-03-15 |
2021-05-19 |
Xencor, Inc. |
Heterodimeric proteins
|
|
WO2014194030A2
(en)
*
|
2013-05-31 |
2014-12-04 |
Immunogen, Inc. |
Conjugates comprising cell-binding agents and cytotoxic agents
|
|
AU2014296219A1
(en)
|
2013-08-01 |
2016-02-25 |
Agensys, Inc. |
Antibody drug conjugates (ADC) that bind to CD37 proteins
|
|
PE20160674A1
(es)
|
2013-08-28 |
2016-07-21 |
Stemcentrx Inc |
Metodos de conjugacion de anticuerpos especificos de sitio y composiciones
|
|
EP3338793A1
(en)
|
2013-08-28 |
2018-06-27 |
AbbVie Stemcentrx LLC |
Novel sez6 modulators and methods of use
|
|
US9765142B2
(en)
|
2013-10-11 |
2017-09-19 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
TEM8 antibodies and their use in treatment and detection of tumors
|
|
HUE055190T2
(hu)
|
2013-10-11 |
2021-12-28 |
Oxford Bio Therapeutics Ltd |
Konjugált antitestek LY75 elleni rák kezelésére
|
|
BR112016007622A2
(pt)
|
2013-10-15 |
2018-01-23 |
Seattle Genetics, Inc. |
composto, composição farmacêutica, conjugado de ligante-droga, e, método para tratar câncer
|
|
US20160280798A1
(en)
|
2013-11-06 |
2016-09-29 |
The United States Of America, As Represented By The Secretary Department Of Health & Human Service |
Alk antibodies, conjugates, and chimeric antigen receptors, and their use
|
|
WO2015077605A1
(en)
|
2013-11-25 |
2015-05-28 |
Seattle Genetics, Inc. |
Preparing antibodies from cho cell cultures for conjugation
|
|
WO2015103549A1
(en)
|
2014-01-03 |
2015-07-09 |
The United States Of America, As Represented By The Secretary Department Of Health And Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
|
CA2936377A1
(en)
|
2014-01-10 |
2015-07-16 |
Shanghai Birdie Biotech, Inc. |
Compounds and compositions for treating egfr expressing tumors
|
|
EA201691683A1
(ru)
|
2014-02-21 |
2017-04-28 |
ЭББВИ СТЕМСЕНТРКС ЭлЭлСи |
Антитела против dll3 и конъюгаты антитело-лекарственное средство для применения при меланоме
|
|
AU2014384434B2
(en)
|
2014-02-28 |
2016-11-03 |
Hangzhou Dac Biotech Co., Ltd |
Charged linkers and their uses for conjugation
|
|
CN110845616A
(zh)
|
2014-03-21 |
2020-02-28 |
艾伯维公司 |
抗-egfr抗体及抗体药物偶联物
|
|
WO2015149001A1
(en)
|
2014-03-27 |
2015-10-01 |
The Brigham And Women's Hospital, Inc. |
Metabolically-activated drug conjugates to overcome resistance in cancer therapy
|
|
EP3954713A3
(en)
|
2014-03-28 |
2022-03-30 |
Xencor, Inc. |
Bispecific antibodies that bind to cd38 and cd3
|
|
US20160060360A1
(en)
|
2014-07-24 |
2016-03-03 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
|
CN112546238A
(zh)
|
2014-09-01 |
2021-03-26 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-pd-l1结合物
|
|
PT3221349T
(pt)
|
2014-11-19 |
2021-01-21 |
Axon Neuroscience Se |
Anticorpos tau humanizados na doença de alzheimer
|
|
CN116333153A
(zh)
|
2014-11-26 |
2023-06-27 |
森科股份有限公司 |
结合cd3和肿瘤抗原的异二聚体抗体
|
|
EP3223907A2
(en)
|
2014-11-26 |
2017-10-04 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cd38
|
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
|
WO2016105450A2
(en)
|
2014-12-22 |
2016-06-30 |
Xencor, Inc. |
Trispecific antibodies
|
|
US10227411B2
(en)
|
2015-03-05 |
2019-03-12 |
Xencor, Inc. |
Modulation of T cells with bispecific antibodies and FC fusions
|
|
EP3265474A1
(en)
|
2015-03-05 |
2018-01-10 |
Sirenas LLC |
Cyclic peptide analogs and conjugates thereof
|
|
US9974865B2
(en)
|
2015-03-09 |
2018-05-22 |
Agensys, Inc. |
Antibody drug conjugates (ADC) that bind to FLT3 proteins
|
|
EP3091033A1
(en)
|
2015-05-06 |
2016-11-09 |
Gamamabs Pharma |
Anti-human-her3 antibodies and uses thereof
|
|
EP4286511A3
(en)
|
2015-06-12 |
2024-03-06 |
Lentigen Technology, Inc. |
Method to treat cancer with engineered t-cells
|
|
SG10202005460RA
(en)
|
2015-06-30 |
2020-07-29 |
Seattle Genetics Inc |
Anti-ntb-a antibodies and related compositions and methods
|
|
NZ739830A
(en)
|
2015-07-12 |
2021-12-24 |
Hangzhou Dac Biotech Co Ltd |
Bridge linkers for conjugation of cell-binding molecules
|
|
US9839687B2
(en)
|
2015-07-15 |
2017-12-12 |
Suzhou M-Conj Biotech Co., Ltd. |
Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
|
|
EP3347047A1
(en)
|
2015-09-09 |
2018-07-18 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Expression vector delivery system and use thereof for inducing an immune response
|
|
EP3359570A1
(en)
|
2015-10-07 |
2018-08-15 |
The U.S.A. As Represented By The Secretary, Department Of Health And Human Services |
Il-7r-alpha specific antibodies for treating acute lymphoblastic leukemia
|
|
CN114181960B
(zh)
|
2015-10-09 |
2024-08-23 |
美天施生物科技有限公司 |
嵌合抗原受体和使用方法
|
|
WO2017066714A1
(en)
|
2015-10-16 |
2017-04-20 |
Compugen Ltd. |
Anti-vsig1 antibodies and drug conjugates
|
|
KR20180085800A
(ko)
|
2015-12-07 |
2018-07-27 |
젠코어 인코포레이티드 |
Cd3 및 psma에 결합하는 이종이합체성 항체
|
|
WO2017147597A1
(en)
|
2016-02-27 |
2017-08-31 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Peptide vaccines comprising self-assembling polymer nanoparticles
|
|
KR102456433B1
(ko)
|
2016-03-02 |
2022-10-19 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
에리불린-기반 항체-약물 콘주게이트 및 사용 방법
|
|
MA45324A
(fr)
|
2016-03-15 |
2019-01-23 |
Seattle Genetics Inc |
Polythérapie utilisant un adc-liv1 et un agent chimiothérapeutique
|
|
BR112018069273A2
(pt)
|
2016-03-25 |
2019-01-22 |
Seattle Genetics Inc |
métodos para preparação de um composto e para tratamento de um indivíduo com uma malignidade hematológica, composto, composição, e, intermediário ligante de fármaco ou composto ligante de fármaco
|
|
JP2019522960A
(ja)
|
2016-04-21 |
2019-08-22 |
アッヴィ・ステムセントルクス・エル・エル・シー |
新規の抗ｂｍｐｒ１ｂ抗体及び使用方法
|
|
US11016085B2
(en)
|
2016-04-25 |
2021-05-25 |
The Johns Hopkins University |
ZNT8 assays for drug development and pharmaceutical compositions
|
|
CN109563167A
(zh)
|
2016-06-08 |
2019-04-02 |
艾伯维公司 |
抗b7-h3抗体和抗体药物偶联物
|
|
PL3458479T4
(pl)
|
2016-06-08 |
2021-07-26 |
Abbvie Inc. |
Przeciwciała anty-b7-h3 i koniugaty przeciwciało-lek
|
|
WO2017214456A1
(en)
|
2016-06-08 |
2017-12-14 |
Abbvie Inc. |
Anti-cd98 antibodies and antibody drug conjugates
|
|
MX2018015272A
(es)
|
2016-06-08 |
2019-08-12 |
Abbvie Inc |
Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
|
|
WO2017214339A1
(en)
|
2016-06-08 |
2017-12-14 |
Abbvie Inc. |
Anti-b7-h3 antibodies and antibody drug conjugates
|
|
IL263542B2
(en)
|
2016-06-14 |
2024-10-01 |
Xencor Inc |
Bispecific antibodies inhibit immunological checkpoint
|
|
KR20190020341A
(ko)
|
2016-06-28 |
2019-02-28 |
젠코어 인코포레이티드 |
소마토스타틴 수용체 2에 결합하는 이종이량체 항체
|
|
BR112019001945A2
(pt)
|
2016-08-09 |
2019-05-07 |
Seattle Genetics, Inc. |
composição de conjugado de fármaco aglutinante, formulação farmaceuticamente aceitável, métodos para tratar uma doença ou afecção hiperproliferativa, para inibir a multiplicação de uma célula tumoral ou célula cancerígena e para preparar uma composição de conjugado de fármaco aglutinado, e, composto
|
|
US11254705B2
(en)
|
2016-09-02 |
2022-02-22 |
Sirenas Llc |
Cyclic peptide analogs and conjugates thereof
|
|
CN117298260A
(zh)
|
2016-09-02 |
2023-12-29 |
莱蒂恩技术公司 |
用DuoCAR治疗癌症的组合物和方法
|
|
CN110214148A
(zh)
|
2016-10-14 |
2019-09-06 |
Xencor股份有限公司 |
含有IL-15/IL-15Rα Fc融合蛋白和PD-1抗体片段的双特异性异源二聚体融合蛋白
|
|
KR102345175B1
(ko)
|
2016-11-14 |
2021-12-31 |
항저우 디에이씨 바이오테크 씨오, 엘티디 |
결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
|
|
JP7350313B2
(ja)
|
2016-12-16 |
2023-09-26 |
ブルーフィン バイオメディシン， インコーポレイテッド |
抗ｃｕｂドメイン含有タンパク質１（ｃｄｃｐ１）抗体、抗体薬物コンジュゲート、およびその使用方法
|
|
CN117946283A
(zh)
|
2017-01-09 |
2024-04-30 |
莱蒂恩技术公司 |
用于用抗间皮素免疫治疗癌症的组合物和方法
|
|
CN110392697A
(zh)
|
2017-03-02 |
2019-10-29 |
国家医疗保健研究所 |
对nectin-4具有特异性的抗体及其用途
|
|
GB201703876D0
(en)
|
2017-03-10 |
2017-04-26 |
Berlin-Chemie Ag |
Pharmaceutical combinations
|
|
US11730822B2
(en)
|
2017-03-24 |
2023-08-22 |
Seagen Inc. |
Process for the preparation of glucuronide drug-linkers and intermediates thereof
|
|
WO2018175988A1
(en)
|
2017-03-24 |
2018-09-27 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd33 immunotherapy
|
|
BR112019020853A2
(pt)
|
2017-04-04 |
2020-05-12 |
Avidea Technologies, Inc. |
Vacinas à base de peptídeo, métodos de fabricação e usos das mesmas para induzir uma resposta imune
|
|
EP3607319A1
(en)
|
2017-04-07 |
2020-02-12 |
Juno Therapeutics, Inc. |
Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods
|
|
US11932694B2
(en)
|
2017-04-19 |
2024-03-19 |
Bluefin Biomedicine, Inc. |
Anti-VTCN1 antibodies and antibody drug conjugates
|
|
EP3617235A4
(en)
|
2017-04-28 |
2020-12-16 |
Ajinomoto Co., Inc. |
COMPOUND CONTAINING A SUBSTANCE HAVING AFFINITY FOR A SOLUBLE PROTEIN, CLIVABLE FRACTION, AND REACTIVE GROUP, OR SALT OF THE SAME
|
|
CN118994394A
(zh)
|
2017-06-12 |
2024-11-22 |
蓝鳍生物医药公司 |
抗-il1rap抗体和抗体药物缀合物
|
|
AU2018291497A1
(en)
|
2017-06-30 |
2020-01-16 |
Xencor, Inc. |
Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains
|
|
US11892457B2
(en)
|
2017-07-12 |
2024-02-06 |
The Johns Hopkins University |
Proteoliposome-based ZnT8 self-antigen for type 1 diabetes diagnosis
|
|
EP3661964A1
(en)
|
2017-07-31 |
2020-06-10 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd19/cd20 immunotherapy
|
|
WO2019030574A1
(en)
|
2017-08-10 |
2019-02-14 |
Cerenis Therapeutics Holding |
Cargomers
|
|
CA3075915A1
(en)
|
2017-09-15 |
2019-03-21 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd19 immunotherapy
|
|
CN118345102A
(zh)
|
2017-10-16 |
2024-07-16 |
莱蒂恩技术公司 |
用于用抗cd22免疫治疗来治疗癌症的组合物和方法
|
|
JP7381478B2
(ja)
|
2017-10-23 |
2023-11-15 |
マブリンク ビオシオンス |
単一分子量ポリサルコシンを含むリガンド－薬物－複合体
|
|
US10386338B2
(en)
|
2017-10-30 |
2019-08-20 |
Cynthia Rena Wright |
DNA/RNA PEMS microcantilever probe for detection of viral infection and detection of genetic variants
|
|
EP3703711A4
(en)
|
2017-11-03 |
2021-01-13 |
Lentigen Technology, Inc. |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER WITH ANTI-MMR1 IMMUNOTHERAPY
|
|
AU2018366199A1
(en)
|
2017-11-08 |
2020-05-28 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-PD-1 sequences
|
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
KR20200094181A
(ko)
|
2017-11-29 |
2020-08-06 |
마젠타 테라퓨틱스 인코포레이티드 |
Cd5+ 세포를 고갈시키기 위한 조성물 및 방법
|
|
AR113862A1
(es)
|
2017-12-01 |
2020-06-17 |
Seattle Genetics Inc |
Anticuerpos anti-cd47 y sus usos para tratar cáncer
|
|
MX2020005640A
(es)
|
2017-12-01 |
2020-08-20 |
Seattle Genetics Inc |
Anticuerpos anti-liv1 humanizados para el tratamiento de cancer de mama.
|
|
MX2020006322A
(es)
|
2017-12-19 |
2020-09-18 |
Xencor Inc |
Proteinas de fusion il-2 fc modificadas.
|
|
CN111954677A
(zh)
|
2017-12-20 |
2020-11-17 |
莱蒂恩技术公司 |
用于用免疫治疗来治疗hiv/aids的组合物和方法
|
|
WO2019183131A1
(en)
|
2018-03-19 |
2019-09-26 |
Bioventures, Llc |
Periostin antibodies and methods of using the same
|
|
US20210024628A1
(en)
|
2018-03-22 |
2021-01-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for modulating innate lymphoid cell activity, antibody drug conjugates and uses in therapy
|
|
SG11202009264WA
(en)
|
2018-03-23 |
2020-10-29 |
Seattle Genetics Inc |
Use of antibody drug conjugates comprising tubulin disrupting agents to treat solid tumor
|
|
MX2020009991A
(es)
|
2018-03-28 |
2020-10-14 |
Axon Neuroscience Se |
Metodos basados en anticuerpos para detectar y tratar la enfermedad de alzheimer.
|
|
CN112469477A
(zh)
|
2018-04-04 |
2021-03-09 |
Xencor股份有限公司 |
与成纤维细胞活化蛋白结合的异源二聚体抗体
|
|
AU2019256539A1
(en)
|
2018-04-18 |
2020-11-26 |
Xencor, Inc. |
PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof
|
|
EP3781598A1
(en)
|
2018-04-18 |
2021-02-24 |
Xencor, Inc. |
Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
|
|
US20210113705A1
(en)
|
2018-05-22 |
2021-04-22 |
Avidea Technologies, Inc. |
Improved methods of manufacturing peptide-based vaccines
|
|
IL305431B2
(en)
|
2018-06-01 |
2025-03-01 |
Eisai R&D Man Co Ltd |
Antibody-drug conjugates of splicing modulators and methods of use
|
|
CN112262152A
(zh)
|
2018-06-14 |
2021-01-22 |
味之素株式会社 |
具有针对抗体的亲和性物质、切割性部分及反应性基团的化合物或其盐
|
|
GB201809746D0
(en)
|
2018-06-14 |
2018-08-01 |
Berlin Chemie Ag |
Pharmaceutical combinations
|
|
WO2019240288A1
(ja)
|
2018-06-14 |
2019-12-19 |
味の素株式会社 |
抗体に対する親和性物質、および生体直交性官能基を有する化合物またはその塩
|
|
MY208638A
(en)
|
2018-07-02 |
2025-05-21 |
Amgen Inc |
Anti-steap1 antigen-binding protein
|
|
JP2021532116A
(ja)
|
2018-07-23 |
2021-11-25 |
マジェンタ セラピューティクス インコーポレイテッドMagenta Therapeutics, Inc. |
同種異系の細胞療法における抗−ｃｄ５抗体薬物コンジュゲート（ａｄｃ）の使用
|
|
EP3837286A4
(en)
|
2018-08-16 |
2022-08-10 |
The Johns Hopkins University |
ANTIBODIES TO HUMAN ZNT8
|
|
AU2019343184A1
(en)
|
2018-09-20 |
2021-04-15 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-CD123 immunotherapy
|
|
JP7546554B2
(ja)
|
2018-09-26 |
2024-09-06 |
レンティジェン・テクノロジー・インコーポレイテッド |
抗ｃｄ１９／ｃｄ２２免疫療法によりがんを処置するための組成物および方法
|
|
WO2020072681A1
(en)
|
2018-10-03 |
2020-04-09 |
Avidea Technologies, Inc. |
Aromatic ring substituted amphiphilic polymers as drug delivery systems
|
|
SG11202103192RA
(en)
|
2018-10-03 |
2021-04-29 |
Xencor Inc |
Il-12 heterodimeric fc-fusion proteins
|
|
WO2020090979A1
(ja)
|
2018-10-31 |
2020-05-07 |
味の素株式会社 |
抗体に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩
|
|
EP3886895A1
(en)
|
2018-11-30 |
2021-10-06 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd38 immunotherapy
|
|
AU2019392090A1
(en)
|
2018-12-03 |
2021-06-17 |
Agensys, Inc. |
Pharmaceutical compositions comprising anti-191P4D12 antibody drug conjugates and methods of use thereof
|
|
KR20210102274A
(ko)
|
2018-12-13 |
2021-08-19 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
헤르복시디엔 항체-약물 접합체 및 사용 방법
|
|
JP2022514348A
(ja)
*
|
2018-12-21 |
2022-02-10 |
シージェン インコーポレイテッド |
チオール多重リンカーを有するａｄｃ
|
|
AU2020219732A1
(en)
|
2019-02-05 |
2021-08-05 |
Seagen Inc. |
Anti-CD228 antibodies and antibody-drug conjugates
|
|
AU2020232605A1
(en)
|
2019-03-01 |
2021-10-21 |
Xencor, Inc. |
Heterodimeric antibodies that bind ENPP3 and CD3
|
|
JP7650809B2
(ja)
|
2019-03-06 |
2025-03-25 |
レンティジェン・テクノロジー・インコーポレイテッド |
自己駆動型キメラ抗原受容体を用いてがんを処置するための組成物および方法
|
|
MX2021011330A
(es)
|
2019-03-20 |
2021-12-10 |
Univ California |
Anticuerpos de claudina-6 y conjugados de fármacos.
|
|
JP7682797B2
(ja)
|
2019-03-20 |
2025-05-26 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
クローディン６二重特異性抗体
|
|
WO2020214858A1
(en)
|
2019-04-17 |
2020-10-22 |
Avidea Technologies, Inc. |
Compositions and methods of manufacturing star polymers for ligand display and/or drug delivery
|
|
WO2020216947A1
(en)
|
2019-04-24 |
2020-10-29 |
Heidelberg Pharma Research Gmbh |
Amatoxin antibody-drug conjugates and uses thereof
|
|
EP3976653A1
(en)
|
2019-05-30 |
2022-04-06 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-bcma immunotherapy
|
|
US20220306727A1
(en)
|
2019-06-05 |
2022-09-29 |
Seagen Inc. |
Methods of Purifying Masked Antibodies
|
|
US20220233709A1
(en)
|
2019-06-05 |
2022-07-28 |
Seagen Inc. |
Masked Antibody Formulations
|
|
EP3994173A1
(en)
|
2019-07-02 |
2022-05-11 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Monoclonal antibodies that bind egfrviii and their use
|
|
BR112022001045A2
(pt)
|
2019-07-22 |
2022-07-19 |
Seagen Inc |
Método para tratar um indivíduo com ou em risco de desenvolver um câncer associado a liv1, e, kit
|
|
US12366570B2
(en)
|
2019-10-01 |
2025-07-22 |
The Johns Hopkins University |
Cell-based ZNT8 assay
|
|
JP7671284B2
(ja)
|
2019-10-04 |
2025-05-01 |
ティーエーイー ライフ サイエンシーズ |
Ｆｃ変異および部位特異的コンジュゲーション特性を含む抗体組成物
|
|
EP4038101A2
(en)
|
2019-10-04 |
2022-08-10 |
Seagen Inc. |
Anti-pd-l1 antibodies and antibody-drug conjugates
|
|
EP3812008A1
(en)
|
2019-10-23 |
2021-04-28 |
Gamamabs Pharma |
Amh-competitive antagonist antibody
|
|
US20230040928A1
(en)
|
2019-12-09 |
2023-02-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies having specificity to her4 and uses thereof
|
|
WO2021142086A1
(en)
|
2020-01-08 |
2021-07-15 |
Synthis Therapeutics, Inc. |
Alk5 inhibitor conjugates and uses thereof
|
|
WO2021224186A1
(en)
|
2020-05-04 |
2021-11-11 |
Institut Curie |
New pyridine derivatives as radiosensitizers
|
|
CA3180683A1
(en)
|
2020-05-12 |
2021-11-18 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
New method to treat cutaneous t-cell lymphomas and tfh derived lymphomas
|
|
WO2021231976A1
(en)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
|
|
CN116096752B
(zh)
|
2020-06-05 |
2025-10-28 |
卫材R&D管理有限公司 |
抗bcma抗体-药物缀合物及其使用方法
|
|
JPWO2021251358A1
(enExample)
|
2020-06-09 |
2021-12-16 |
|
|
|
EP4168437A1
(en)
|
2020-06-22 |
2023-04-26 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with tslpr-cd19 or tslpr-cd22 immunotherapy
|
|
IL300176A
(en)
|
2020-08-04 |
2023-03-01 |
Seagen Inc |
Anti-CD228 antibodies and antibody-drug conjugates
|
|
EP3970752A1
(en)
|
2020-09-17 |
2022-03-23 |
Merck Patent GmbH |
Molecules with solubility tag and related methods
|
|
US20230381112A1
(en)
|
2020-09-22 |
2023-11-30 |
Vaccitech North America, Inc. |
Compositions and Methods of Manufacturing Amphiphilic Block Copolymers that Form Nanoparticles in Situ
|
|
US20220112274A1
(en)
|
2020-09-28 |
2022-04-14 |
Seagen Inc. |
Humanized anti-liv1 antibodies for the treatment of cancer
|
|
JP2023543498A
(ja)
|
2020-10-01 |
2023-10-16 |
アビオニクス ファーマ エスエー |
脂質結合タンパク質ベースの複合体を使用した、眼疾患を治療するための方法
|
|
EP4228701A1
(en)
|
2020-10-19 |
2023-08-23 |
Vaccitech North America, Inc. |
Star polymer drug conjugates
|
|
CA3196243A1
(en)
|
2020-10-20 |
2022-04-28 |
Angela Marinetti |
Metallic trans-(n-heterocyclic carbene)-amine-platinum complexes and uses thereof for treating cancer
|
|
CA3171093A1
(en)
|
2020-11-05 |
2022-05-12 |
Dina SCHNEIDER |
Compositions and methods for treating cancer with anti-cd19/cd22 immunotherapy
|
|
KR20230133289A
(ko)
|
2021-01-18 |
2023-09-19 |
아지노모토 가부시키가이샤 |
화합물 또는 이의 염, 및 이들에 의해 얻어지는 항체
|
|
KR20230133294A
(ko)
|
2021-01-18 |
2023-09-19 |
아지노모토 가부시키가이샤 |
화합물 또는 그 염, 및 그것들에 의해 얻어지는 항체
|
|
AR124681A1
(es)
|
2021-01-20 |
2023-04-26 |
Abbvie Inc |
Conjugados anticuerpo-fármaco anti-egfr
|
|
MX2023009417A
(es)
|
2021-02-16 |
2023-12-01 |
Vaccitech North America Inc |
Nanopartículas de autoensamblaje basadas en péptidos anfifílicos.
|
|
JP2024511319A
(ja)
|
2021-03-09 |
2024-03-13 |
ゼンコア インコーポレイテッド |
Ｃｄ３及びｃｌｄｎ６に結合するヘテロ二量体抗体
|
|
JP2024509274A
(ja)
|
2021-03-10 |
2024-02-29 |
ゼンコア インコーポレイテッド |
Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体
|
|
CN116964076A
(zh)
|
2021-03-11 |
2023-10-27 |
味之素株式会社 |
化合物或其盐、以及由它们得到的抗体
|
|
WO2022189618A1
(en)
|
2021-03-12 |
2022-09-15 |
Institut Curie |
Nitrogen-containing heterocycles as radiosensitizers
|
|
EP4310096A4
(en)
|
2021-03-16 |
2025-06-25 |
Ajinomoto Co., Inc. |
Complex or salt thereof, and method for manufacturing same
|
|
US12036286B2
(en)
|
2021-03-18 |
2024-07-16 |
Seagen Inc. |
Selective drug release from internalized conjugates of biologically active compounds
|
|
CN117241832A
(zh)
|
2021-03-19 |
2023-12-15 |
海德堡医药研究有限责任公司 |
B淋巴细胞特异性的鹅膏毒素抗体缀合物
|
|
KR20220136267A
(ko)
|
2021-03-30 |
2022-10-07 |
주식회사 레고켐 바이오사이언스 |
인간 cldn18.2에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도
|
|
WO2022217022A1
(en)
|
2021-04-10 |
2022-10-13 |
Profoundbio Us Co. |
Folr1 binding agents, conjugates thereof and methods of using the same
|
|
JP2024514154A
(ja)
|
2021-04-15 |
2024-03-28 |
アビオニクス ファーマ エスエー |
臓器保存溶液における脂質結合タンパク質ベースの複合体の使用
|
|
CN117203238A
(zh)
|
2021-04-23 |
2023-12-08 |
普方生物制药美国公司 |
Cd70结合剂、其偶联物及其使用方法
|
|
TW202320857A
(zh)
|
2021-07-06 |
2023-06-01 |
美商普方生物製藥美國公司 |
連接子、藥物連接子及其結合物及其使用方法
|
|
EP4370211A1
(en)
|
2021-07-14 |
2024-05-22 |
Seagen Inc. |
Antibody masking domains
|
|
EP4387666A4
(en)
|
2021-08-20 |
2025-07-16 |
Univ Johns Hopkins |
CELL SURFACE ANTIBODY FOR A PANCREATIC BETA CELL SPECIFIC BIOMARKER
|
|
US20240376200A1
(en)
|
2021-09-24 |
2024-11-14 |
Seagen Inc. |
Improved Antibody Masking Domains
|
|
JPWO2023054706A1
(enExample)
|
2021-09-30 |
2023-04-06 |
|
|
|
CA3236930A1
(en)
|
2021-11-03 |
2022-04-21 |
Hangzhou Dac Biotech Co., Ltd. |
Specific conjugation of an antibody
|
|
JP2024540451A
(ja)
|
2021-11-18 |
2024-10-31 |
オックスフォード バイオセラピューティックス リミテッド |
組合せ医薬
|
|
WO2023092099A1
(en)
|
2021-11-19 |
2023-05-25 |
Ardeagen Corporation |
Gpc3 binding agents, conjugates thereof and methods of using the same
|
|
US11590169B1
(en)
|
2022-03-02 |
2023-02-28 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-CD123 immunotherapy
|
|
US20230338424A1
(en)
|
2022-03-02 |
2023-10-26 |
Lentigen Technology, Inc. |
Compositions and Methods for Treating Cancer with Anti-CD123 Immunotherapy
|
|
CR20240415A
(es)
|
2022-03-09 |
2024-11-07 |
Astrazeneca Ab |
MOLÉCULAS DE UNIÓN CONTRA FRa
|
|
AU2023229967A1
(en)
|
2022-03-11 |
2024-08-08 |
Astrazeneca Ab |
A SCORING METHOD FOR AN ANTI-FRα ANTIBODY-DRUG CONJUGATE THERAPY
|
|
EP4504150A1
(en)
|
2022-04-06 |
2025-02-12 |
Abionyx Pharma SA |
Methods for treating eye diseases using lipid binding protein-based complexes
|
|
US20230355792A1
(en)
|
2022-04-07 |
2023-11-09 |
Heidelberg Pharma Research Gmbh |
Methods of improving the therapeutic index
|
|
EP4562043A2
(en)
|
2022-07-28 |
2025-06-04 |
Lentigen Technology, Inc. |
Chimeric antigen receptor therapies for treating solid tumors
|
|
CN119907810A
(zh)
|
2022-08-26 |
2025-04-29 |
莱蒂恩技术公司 |
用于用全人抗cd20/cd19免疫治疗来治疗癌症的组合物和方法
|
|
WO2024052503A1
(en)
|
2022-09-08 |
2024-03-14 |
Institut National de la Santé et de la Recherche Médicale |
Antibodies having specificity to ltbp2 and uses thereof
|
|
CA3267628A1
(en)
|
2022-09-21 |
2024-03-28 |
Seagen Inc |
ANTIBODIES THAT BIND TO CD228
|
|
IL320235A
(en)
|
2022-10-25 |
2025-06-01 |
Barinthus Biotherapeutics North America Inc |
Self-assembled nanoparticles
|
|
EP4608437A2
(en)
|
2022-10-25 |
2025-09-03 |
Barinthus Biotherapeutics North America, Inc. |
Combination treatment regimes for treating cancer
|
|
CN120187759A
(zh)
|
2022-11-01 |
2025-06-20 |
海德堡医药研究有限责任公司 |
抗gucy2c抗体及其用途
|
|
WO2024097816A1
(en)
|
2022-11-03 |
2024-05-10 |
Seagen Inc. |
Anti-avb6 antibodies and antibody-drug conjugates and their use in the treatment of cancer
|
|
EP4382120A1
(en)
|
2022-12-05 |
2024-06-12 |
Institut Regional du Cancer de Montpellier |
Anti-slc1a4 monoclonal antibodies and uses thereof
|
|
WO2024121632A1
(en)
|
2022-12-09 |
2024-06-13 |
Crispr Therapeutics Ag |
Use of anti-cd117 antibody drug conjugate (adc)
|
|
KR20250148670A
(ko)
|
2023-02-16 |
2025-10-14 |
아스트라제네카 아베 |
치료용 결합 분자를 사용한 암 치료를 위한 병용 요법
|
|
KR20250152101A
(ko)
|
2023-03-13 |
2025-10-22 |
하이델베르크 파마 리서치 게엠베하 |
암 치료에의 사용을 위한 피하 투여 항체-약물 접합체
|
|
CN120917041A
(zh)
|
2023-04-04 |
2025-11-07 |
味之素株式会社 |
抗体和功能性物质的缀合物、抗体衍生物以及化合物或它们的盐
|
|
CN121039143A
(zh)
|
2023-04-05 |
2025-11-28 |
味之素株式会社 |
抗体和功能性物质的缀合物或其盐、以及具有硫醇基的抗体中间体或其盐
|
|
AU2024273407A1
(en)
|
2023-05-17 |
2025-12-04 |
Centre National De La Recherche Scientifique |
Anti-cathepsin-d antibodies
|
|
WO2024258743A1
(en)
|
2023-06-13 |
2024-12-19 |
Adcentrx Therapeutics, Inc. |
Methods and compositions related to antibodies and antibody drug conjugates (adcs) that bind nectin-4 proteins
|
|
WO2024258967A1
(en)
|
2023-06-13 |
2024-12-19 |
Synthis Therapeutics, Inc. |
Anti-cd5 antibodies and their uses
|
|
WO2025014896A1
(en)
|
2023-07-07 |
2025-01-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Humanized 40h3 antibody
|
|
WO2025021928A1
(en)
|
2023-07-25 |
2025-01-30 |
Merck Patent Gmbh |
Iduronidase-cleavable compounds
|
|
WO2025027529A1
(en)
|
2023-07-31 |
2025-02-06 |
Advesya |
Anti-il-1rap antibody drug conjugates and methods of use thereof
|
|
EP4509142A1
(en)
|
2023-08-16 |
2025-02-19 |
Ona Therapeutics S.L. |
Fgfr4 as target in cancer treatment
|
|
EP4512427A1
(en)
|
2023-08-25 |
2025-02-26 |
Mablink Bioscience |
Antibody-drug conjugates based on molecular glue degraders and uses thereof
|
|
AR133955A1
(es)
|
2023-09-26 |
2025-11-19 |
Profoundbio Us Co |
Agentes de unión a ptk7, conjugados de éstos y métodos de uso de los mismos
|
|
WO2025109097A2
(en)
|
2023-11-24 |
2025-05-30 |
Heidelberg Pharma Research Gmbh |
Novel nicotinamide phosphoribosyltransferase inhibitors and uses thereof
|
|
TW202530255A
(zh)
|
2023-12-15 |
2025-08-01 |
法商亞維西亞有限公司 |
抗ｉｌ－１ｒａｐ結合結構域及其抗體－藥物偶聯物
|
|
WO2025149661A1
(en)
|
2024-01-10 |
2025-07-17 |
Genmab A/S |
Slitrk6 binding agents, conjugates thereof and methods of using the same
|
|
WO2025163468A1
(en)
|
2024-01-30 |
2025-08-07 |
Seagen Inc. |
Anti-pd-l1 antibodies and antibody-drug conjugates and their use in the treatment of cancer
|
|
WO2025181219A1
(en)
|
2024-02-29 |
2025-09-04 |
Genmab A/S |
Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same
|
|
WO2025196639A1
(en)
|
2024-03-21 |
2025-09-25 |
Seagen Inc. |
Cd25 antibodies, antibody-drug conjugates, and uses thereof
|
|
WO2025224297A1
(en)
|
2024-04-26 |
2025-10-30 |
Institut National de la Santé et de la Recherche Médicale |
Antibodies having specificity to tgfbi and uses thereof
|
|
WO2025248097A2
(en)
|
2024-05-31 |
2025-12-04 |
Gamamabs Pharma |
Humanized anti-human her3 antibodies and uses thereof
|